Introduction {#S0001}
============

Pain is a major complication in patients suffering from advanced cancer. While the prevalence of pain in early-stage cancer is estimated at 33%, this percentage nearly doubles in patients with metastatic disease.[@CIT0001],[@CIT0002]

Cancer pain is classified into two distinct categories: persistent background pain, and transitory severe pain exacerbation, known as breakthrough cancer pain (BTcP).[@CIT0003]

BTcP is a specific pain syndrome mainly caused by the neoplasm itself (70--80% of cases).[@CIT0004] Breakthrough pain is often caused by bone metastases, which are common in patients with breast, prostate, and lung cancer.[@CIT0005],[@CIT0006] Most patients with bone metastases experience acute severe pain that is often localized to a particular area.[@CIT0007],[@CIT0008] As cancer pain progresses in severity it can aggravate the physical impairment and movement limitation produced by bone metastasis, and can also severely undermine the patient's health-related quality of life (HRQoL).[@CIT0005],[@CIT0009] Pain related to bone metastasis should be managed with analgesic drugs. According to the World Health Organization (WHO), mild pain should be treated with NSAIDs (non-steroidal anti-inflammatory drugs) and paracetamol, whereas weak opioids are the treatment of choice for mild to moderate pain. Finally, moderate to severe pain should be managed with strong opioids.[@CIT0010]--[@CIT0012] In this context, the onset of intense breakthrough pain demands fast-acting therapy to control the pain and improve functionality in bone metastatic patients. There are numerous pharmaceutical and non-pharmaceutical options currently available for BTcP, a condition that presents a significant challenge to medical specialists.

In this context, rapid-onset opioids (ROOs) have been shown to provide faster acting and more effective pain relief than traditional immediate-release morphine or placebo.[@CIT0013] Based on this evidence, the latest versions of the Spanish Society of Medical Oncology (SEOM)[@CIT0004] and the European Society for Medical Oncology (ESMO)[@CIT0014] guidelines consider ROOs to be more suited to breakthrough pain than immediate-release morphine, and recommend them as the first option to treat BTcP.

Despite these recommendations and the growing evidence supporting the use of ROOs in recent years, some studies[@CIT0015],[@CIT0016] suggest that a high proportion of cancer patients receive suboptimal analgesia. Undertreatment of bone pain is also common, adding a further burden to metastatic disease.[@CIT0017] These data show the need to improve the treatment strategy in patients with bone-related BTcP. However, the management of BTcP in metastatic patients in clinical practice is poorly characterized in our setting. Providing such real-world evidence would help evaluate improvements in BTcP management in future studies. For this purpose, we aimed to explore the characteristics and real-life therapeutic management of patients with BTcP caused by bone metastases. Additionally, we sought to evaluate physician satisfaction with the prescribed BTcP therapy, to ascertain their opinion regarding the key aspects of BTcP treatment, and to identify points of agreement and discrepancy among different specialties involved in treating bone metastatic cancer.

Materials and methods {#S0002}
=====================

An electronic questionnaire was specifically designed to collect real-world data on the management of BTcP associated with bone metastases. It was divided into two domains: 1) organizational aspects and BTcP care standards according to physician opinion; 2) clinical and treatment variables of bone were also assessed. In the second domain, specialists collected clinical data from their patients. For inclusion, patients were required to be older than 18 years, to have received a diagnosis of BTcP caused by bone metastases, and to be receiving treatment for BTcP.

The following organizational aspects of medical units were collected in domain 1) doctors and nurses working full time, catchment area, number of patients with BTcP and metastatic disease seen last month, referral protocol for patients with cancer pain and BTcP associated with metastatic disease, treatment guidelines for cancer pain and BTcP associated with metastatic disease, patient information fact sheets about treatment, regular multidisciplinary tumor board meetings, use of quality of life questionnaires. Physicians were also asked about the percentage of patients with bone BTcP who should be treated with different therapeutic options, which treatment they recommended for BTcP (Likert scale 1--7: 1 never recommended; 7 always recommended), which were the major determinants for the choice of the BTcP treatment (Likert scale 1--7: 1: never taken into account; 7: always taken into account), their level of satisfaction with BTcP treatment in general (Likert scale: 1= extremely dissatisfied; 7= extremely satisfied) and the major determinant of BTcP treatment efficacy (placed in order, 1 being the most important and 5 the least important).

The clinical variables of bone metastatic BTcP patients evaluated in domain 2) were: location of the primary tumor, number of metastases, patient performance status (ECOG scale and Karnofsky Index), characteristics of baseline pain (type and intensity on a visual analog scale \[VAS\]), pharmacological treatment for baseline pain, characteristics of BTcP episodes during the week prior to data collection (number of BTcP episodes per day, duration of BTcP episodes, pain intensity \[VAS\]; BTcP occurrence and cause), pharmacological treatment for BTcP and physicians' satisfaction with this treatment (1=extremely dissatisfied; 7=extremely satisfied). We also recorded if QoL had been determined.

Participants were pain management specialists mainly from radiation oncology (RO) units, palliative care (PC) units, and pain units (PU). All were required to have experience in diagnosing and treating cancer pain. Specialists collected data from up to five patients, and all patients gave their consent to participate. The study was approved by the Ethics Committee of the Consorcio Hospitalario Provincial de Castellón.

Data were analyzed descriptively using R statistics 3.2.5. Categorical variables were described as absolute and relative frequencies; central tendency and dispersion were reported for quantitative variables. The Chi-square test was used for comparisons among different specialties. Statistical significance was set at *p*\<0.05.

Results {#S0003}
=======

A total of 103 cancer pain specialists from RO (n=40/103;38.8%), pain (n=34/103; 33.0%), and PC (n=22/103; 21.4%) units were polled. Mean (±SD) years of experience in the treatment of cancer pain were 12.1±6.7.

Care standards in specialized units {#S0003-S2001}
-----------------------------------

Answers to questions about care standards in specialized units are summarized in [Table 1](#T0001){ref-type="table"}.Table 1Organizational aspects of care unitsQuestionsHow many doctors work in your hospital's unit full-time? Mean (±SD)4.9 (±3.4%)How many nurses work in your hospital's unit full-time? Mean (±SD)3.8 (±3.6%)What is the catchment area of your pain unit? N (%)From 25,000 to 50,000 inhabitants3 (2.9%)From 50,000 to 100,000 inhabitants3 (2.9%)From 100,000 to 200,000 inhabitants20 (19.4%)\>200,000 inhabitants77 (74.8%)How many patients with BTcP and metastatic disease were seen in your unit last month? N (%)\<5 patients16 (15.5%)From 5 to 10 patients44 (42.7%)From 11 to 25 patients33 (32.0%)From 26 to 50 patients5 (4.9%)\>50 patients5 (4.9%)Does your hospital provide the following units or services? N (%)Palliative care87 (84.5%)Medical oncology96 (93.2%)Radiation oncology73 (70.9%)Pain unit90 (87.4%)Hospital at Home Program73 (70.9%)Does your hospital or healthcare department have a referral protocol for monitoring patients with cancer pain? N (%)Yes49 (47.6%)No54 (52.4%)Does your hospital or healthcare department have a referral protocol for monitoring patients with BTcP and metastatic disease? N (%)Yes20 (19.4%)No83 (80.6%)Does your hospital organize regular multidisciplinary tumor board meetings? N (%)Yes, but I do not attend41 (39.8%)Yes, I attend49 (47.6%)No13 (12.6%)Does your care unit use treatment guidelines for cancer pain? N (%)Ye64 (62.1%)No39 (37.9%)Does your care unit use treatment guidelines for BTcP patients with bone metastasis? N (%)YesNo34 (33.0%)\
69 (67.0%)Does your care unit use patient information fact sheets about treatment? N (%) - Yes62 (60.2%) - No41 (39.8%)Does your care unit use quality of life/quality of care questionnaires? N (%) - Yes52 (50.5%) - No51 (49.5%)If yes, do you usually assess quality of life from the patient\'s perspective? N (%) - Yes24 (27.0%) - No65 (73.0%)[^1]

Most physicians polled (n=97/103; 94.2%) were attached to units with a catchment area of \>100,000 inhabitants. Care units had a mean of 4.9±3.4 full-time physicians and 3.8±3.6 full-time nurses. Most respondents (n=77/103; 74.7%) estimated that between 5 and 25 BTcP patients with bone metastases had been seen in their units in the preceding month.

According to pain experts, most of their hospitals had medical oncology departments (n=96/103; 93.2%), PU (n=90/103; 87.4%), or PC units (n=87/103; 84.5%); however, only 19.4% (n=20/103) had implemented a referral protocol for monitoring patients with BTcP and metastatic disease.

Most physicians (\>60%) reported that their units provide patients with printed fact sheets about pain treatment and had protocols for cancer pain treatment and assessment. However, only 33% (n=34/103) had established a specific protocol for BTcP management in patients with bone metastases. When participants were asked about the routine use of HRQoL questionnaires, around half (n=52/103; 50.5%) reported that they address quality of life or quality of care of their BTcP patients. However, only 27.0% (n=24/89) of specialists routinely evaluate quality of care from the patient's perspective in clinical practice.

BTcP therapeutic management according to specialists {#S0003-S2002}
----------------------------------------------------

According to the physicians polled, at least half of all patients suffering from bone BTcP should be treated with strong opioids (n=98/103; 95.1%), followed by analgesic radiotherapy (n=87/103;84.4%) or coanalgesics (n=72/103; 69.9%), while fewer specialists considered that breakthrough pain due to bone metastases should be managed with interventional techniques (n=37/103; 35.9%) or weak opioids (n=10/103; 9.7%). In general, there were no significant differences between specialties, although most physicians that considered interventional techniques to be appropriate belonged to PUs (70.3% vs 21.4% for PC and 5.4% for RO).

Among pharmacotherapies, most respondents recommended transmucosal fentanyl as their treatment of choice for BTcP caused by bone metastases, followed by parenteral opioids (1= least recommended and 7= most recommended) ([Figure 1](#F0001){ref-type="fig"}). There were significant differences between specialties, with more PC physicians choosing parenteral opioids (PC: 5.6±1.4 vs PU: 3.6±1.9 and RO: 3.7±2.0; *p*\<0.0001). There were also significant differences regarding oral transmucosal fentanyl (PC: 6.7±0.8 vs PU: 6.6±0.7 vs RO: 6.2±1.1; *p*\<0.05) and nasal transmucosal fentanyl (PC: 6.6±0.9 vs PU: 6.4±0.7 vs RO: 5.9±1.4; *p*\<0.05) between the three care units. Moreover, experts rated their degree of satisfaction with BTcP therapy (1= extremely dissatisfied; 7= extremely satisfied) with a mean score of 5.4±0.9, with the highest score reported in ROs: 5.8±0.7 followed by PUs: 5.2±0.9 and PCs: 5.1±1.0.Figure 1Physician grade of recommendation for BTcP therapeutic.**Notes:** Physician grade of recommendation for BTcP therapeutic options was assessed using a 7-point Likert scale (where 1= least recommended and 7= most recommended).**Abbreviation:** BTcP, breakthrough cancer pain.

When deciding on the most suitable treatment to address BTcP caused by bone metastases, most experts considered the onset of action (n=80/103; 77.7%) and duration of analgesia (n=71/103; 68.9%) or the route of administration (n=68/103; 66.0%) and the titration method (n=64/103; 62.1%) of the pharmacotherapy. Other characteristics, such as the patient's social support (n=39/103; 37.9%), were less frequently considered when weighing up treatment options. According to most experts, the major determinant of BTcP treatment efficacy was pain intensity (n=53/103; 51.5%), followed by the frequency of BTcP episodes (n=28/103; 27.2%), patient functionality (n=16/103; 15.5%), presence of adverse events (n=4/103; 3.9%) and last, the duration of BTcP episodes (n=2/103; 1.9%).

Real-world data of patients with BTcP caused by bone metastases {#S0003-S2003}
---------------------------------------------------------------

### Characteristics of patients and BTcP episodes {#S0003-S2003-S3001}

Physicians collected data from 386 BTcP patients with metastatic bone disease, of whom 68.1% (n=263/386) were men; mean age was 65.7±12.2 years. Primary tumors were mainly localized in the lungs (n=98/386; 25.4%) and prostate (n=85/386; 22.0%). In 74.9% (n=289/386) of cases, patients had multiple bone metastases. In addition, more than 70% (n=278/386) of patients had an ECOG performance status of 1 or 2 (n=278/386; 72.1%) and a Karnofsky Performance score of between 50 and 80 (n=289/386; 74.9%). Patients had a mean of 3.5±1.8 BTcP episodes per day, mainly characterized by sudden onset, severe intensity (on VAS) and a mean duration of 22.2±17.5 mins ([Table 2](#T0002){ref-type="table"}).Table 2Characteristics of BTcP patients and BTcP episodesCharacteristics of BTcP patientsAge, years (± SD)65.7 (12.2)Gender, n (%) Male263 (68.1) Female123 (31.9)Location of the primary tumor, n (%) Lung98 (25.4) Prostate85 (22.0) Gastrointestinal64 (16.6) Breast63 (16.3) Others76 (19.7)Quantity of bone metastases, n (%) Multiple289 (74.9) Single95 (24.6) NA2 (0.5)ECOG score, n (%) ECOG 0 - Fully active, able to carry on all pre-disease performance without restriction.26 (6.7) ECOG 1 - Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work106 (27.5) ECOG 2 - Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours172 (44.6) ECOG 3 - Capable of only limited self-care, confined to bed or chair more than 50% of waking hours69 (17.9) ECOG 4- Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair12 (3.1)Karnofsky Index, n (%) 20- Very sick; hospital admission necessary; active supportive treatment necessary4 (1.0) 30- Severely disabled; hospital admission is indicated although death not imminent.8 (2.1) 40- Disabled; requires special care and assistance.36 (9.3) 50- Requires considerable assistance and frequent medical care.62 (16.1) 60- Requires occasional assistance but is able to care for most of their personal needs.60 (15.5) 70- Cares for self; unable to carry on normal activity or to do active work.97 (25.1) 80- Normal activity with effort; some signs or symptoms of disease.70 (18.1) 90- Able to carry on normal activity; minor signs or symptoms of disease.41 (10.6) 100- Normal; no complaints; no evidence of disease.8 (2.1)Characteristics of basal painType, n (%) Mixed231 (59.8) Neuropathic32 (8.3) Nociceptive114 (29.5) Procedural8 (2.1) Unknown1 (0.3)Pain intensity (VAS), mean (SD)6.2 (2.1)Characteristics of BTcP Number of BTcP episodes per day, mean (SD)3.5 (1.8) Duration of BTcP episodes, mean (SD)20.2 (17.5)Pain intensity (VAS), n (%) Severe (VAS 7-10)275 (71.2) Moderate (VAS 4-6)103 (26.7) Mild (VAS 0-3)8 (2.1)BTcP occurrence, n (%) Sudden onset236 (61.1) Progressive onset150 (38.9)BTcP occurrence, n (%) Unpredictable214 (55.4) Predictable171 (44.3) No answer1 (0.3)Cause of BTcP, n (%) Spontaneous pain193 (50.0) Incidental pain193 (50.0)[^2]

HRQOL had been assessed in 19.2% (n=74/386) of patients. The cancer-specific EORTC quality of life questionnaire C-30 (EORTC QLQ-C30) was the most commonly used questionnaire, followed by the generic 12-Item Short Form Health Survey (SF-12).

### Pharmacological treatment of BTcP associated with bone metastasis {#S0003-S2003-S3002}

Baseline pain was mainly controlled with transdermal fentanyl (n=160/386; 41.5%), oral morphine (n=35/386; 9.1%) or tapentadol rectally administered (n=27/386; 7.0%) ([Supplementary Table 1](https://www.dovepress.com/get_supplementary_file.php?f=194881.docx)).

Regarding BTcP treatment, most patients (n=275/386; 71.2%) were prescribed rapid-onset fentanyl preparations alone or in combination with other analgesics, followed by immediate-release morphine (n=36/386; 9.3%) and NSAIDs (n=21/386; 5.4%) ([Figure 2](#F0002){ref-type="fig"}; [Supplementary Tables 2](https://www.dovepress.com/get_supplementary_file.php?f=194881.docx) and [3](https://www.dovepress.com/get_supplementary_file.php?f=194881.docx)). The most common route of fentanyl administration among BTcP patients was sublingual (n=187/275; 68.0%), followed by nasal (n=36/275; 13.1%) and oral (n=21/275; 7.6%). The mean fentanyl dose was 214±171 µg. Fentanyl was used on demand, with a frequency of administration of one dose every 4--6 hrs in 55.3% of patients. In most cases (n=266/386; 68.9%), medication was titrated to the lowest effective dose. Dose adjustments had been made for baseline pain management and patient compliance had been assessed before BTcP treatment prescription in most cases. Additionally, fentanyl preparations alone were mainly prescribed when BTcP intensity was severe (n=120/170, 70.6%), and BTcP occurred suddenly (n=108/170, 63.5%) and unpredictably (n=93/169, 55.0%). Approximately half of these cases (49.4%) were spontaneous (n=84/170) ([Supplementary Table 4](https://www.dovepress.com/get_supplementary_file.php?f=194881.docx)).Figure 2Distribution of patients according to type of BTcP treatment.**Abbreviations:** BTcP, breakthrough cancer pain; NSAIDS, nonsteroidal anti-inflammatory drugs.

Rapid-onset fentanyl was the most common medication prescribed in all specialized units; however, PC physicians reported significantly higher rates of prescription compared to RO (79.0% vs 61.1%; *p*\<0.01) and PU (79.0% vs 75.9%; *p*=0.056). The second therapeutic option in PCs was immediate-release morphine, while NSAIDs were the second most common option in PUs ([Figure 3](#F0003){ref-type="fig"}). Furthermore, sublingual fentanyl was prescribed more frequently in PCs (81.4%) than in ROs (79.1%) and PUs (69.5%), although these differences were not statistically significant (*p*\>0.05). In turn, 28% of the patients (n=108) were treated with a combined strategy of pharmaceutical treatment and interventional techniques. The most commonly used techniques for BTcP treatment caused by bone metastases were peripheral nerve blockade (35.2%) and epidural block (25.0%).Figure 3Distribution of patients according to type of BTcP treatment and care units.**Abbreviations:** BTcP, breakthrough cancer pain; NSAIDS, nonsteroidal anti-inflammatory drugs; PC, palliative care; PU, pain units; RO, radiation oncology.

Most physicians (71.8%) were satisfied to some extent with the prescribed BTcP therapy, 15.0% (n=58/386) were neutral, and 13.2% (n=51/386) were dissatisfied with the analgesia given ([Figure 4](#F0004){ref-type="fig"}). Mean satisfaction with treatment was 5±1.4 (1= extremely dissatisfied, 7= extremely satisfied). According to physicians, dissatisfaction with BTcP treatment most frequently resulted from departmental organization issues (n=114/439; 26.0%), while only 13.2% (n=58/439) cited lack of therapeutic efficacy as the main cause of dissatisfaction.Figure 4Distribution of physicians according to degree of satisfaction with BTcP therapy.**Notes:** Physician satisfaction with treatment was assessed using a 7-point Likert scale (where 1= extremely dissatisfied and 7= extremely satisfied).**Abbreviation:** BTcP, breakthrough cancer pain.

Discussion {#S0004}
==========

This study provides a comprehensive description of the characteristics and therapeutic management of patients with BTcP caused by bone metastases in clinical practice. BTcP is a common manifestation of bone malignancy, and greatly affects the emotional and physical health of patients. However, very few studies have previously evaluated BTcP management in this population.

Successful management of BTcP can require a multidisciplinary approach that involves common standards of care and the establishment of referral protocols between services involved in patient management.[@CIT0018] According to the experts polled, very few departments used treatment protocols and specific referral criteria for BTcP patients with bone metastases. These findings underline the need for multidisciplinary strategies to manage BTcP in this specific group of patients.

BTcP management requires the assessment of psychosocial factors, such as social support, cognitive status, or psychological stress, all of which can affect therapeutic efficacy.[@CIT0019] Clinical guidelines agree that cancer pain management in incurable cancer is best provided as part of a multiprofessional PC approach, and all other domains of suffering (psychosocial, spiritual, and existential) need to be carefully addressed («total pain»).[@CIT0020] However, according to our survey only 37.9% of the physicians factored social support into their bone metastases-induced BTcP treatment decision-making.

In addition, our results show that HRQoL assessment tools are not routinely used in patients with metastatic disease. This is consistent with findings reported in other studies,[@CIT0021] suggesting that physicians do not consider measuring quality of life as part of therapeutic management. Several studies have shown that BTcP affects a patient's emotional and physical health as well as their capacity to perform routine tasks and to participate in social activities.[@CIT0021]--[@CIT0023] Because of this, cancer patients consider HRQoL to be as important as survival.[@CIT0022]

Quality of life assessment is also important in patients diagnosed with bone metastases. Although they are generally considered to have limited survival prospects, significant progress in anticancer drugs in the last years has increased their life expectancy. In addition, these patients often suffer skeletal-related events such as fracture which might reduce mobility and increase both pain and anxiety,[@CIT0024] but our clinical practice data confirmed that HRQoL was rarely included as a BTcP treatment outcome in metastatic patients.

Data from cancer patients with multiple bone metastases showed that they had several BTcP episodes per day. BTcP episodes were mainly characterized by sudden and unpredictable onset, severe intensity, and a mean duration of 22.2±17.5 mins, which is somewhat longer than that reported in a broader cancer patient population.[@CIT0025] The ECOG performance status and Karnofsky index score of patients in our study showed that most have impaired functionality that limits their capacity to perform daily activities and to work full time. Despite this, only 15.5% of the specialists considered functionality to be the major determinant of BTcP treatment efficacy.

Conversely, most participants, regardless of their medical specialty, agreed that strong opioids, analgesic radiotherapy, and coanalgesics were the best options for treating BTcP in bone metastatic patients. Radiotherapy has traditionally been the gold-standard treatment for pain induced by bone metastases; however, studies have shown that this only achieves complete pain relief in a small percentage of patients,[@CIT0026] prompting some authors to suggest that bone metastatic pain requires both pharmacological and radiation therapies.[@CIT0027],[@CIT0028] In particular, current ESMO guidelines recommend a single 8 Gy dose of external beam radiotherapy in association with analgesics for patients with painful bone metastases (level of evidence I, degree of recommendation A).[@CIT0014]

The use of interventional techniques in the treatment of BTcP has been controversial. Many guidelines recommend that these interventions should be considered for BTcP in accordance with patient needs.[@CIT0029]--[@CIT0031] However, even though these therapies can prevent BTcP and may improve quality of life, their analgesic efficacy has never been properly assessed.[@CIT0032]

Regarding pharmacological treatment, the specialists polled recommended ROOs, and more specifically transmucosal fentanyl formulations, over immediate-release oral morphine or oxycodone. Immediate-release morphine has traditionally been the first-line rescue medication for BTcP, and is still considered the first therapeutic option by some clinical practice guidelines[@CIT0029] However, following approval of transmucosal fentanyl, oral morphine has been relegated to some selected cases. Specifically, the ESMO guidelines[@CIT0014] recommend the use of ROOs as the first choice for the treatment of unpredictable and rapid-onset BTcP (level of evidence I, degree of recommendation A), and suggest limiting oral opioids such as morphine to the treatment of predictable pain (level of evidence II, degree of recommendation B). Although pain due to bone metastases has been associated with incidental and predictable pain, our patient-specific data showed that only 50% of the patients reported incidental onset of pain, and fewer than half (44.3%) experienced predictable BTcP episodes. This justifies the preference for ROOs over immediate-release morphine or oxycodone among the pain experts polled in our study. Additionally, most metastatic patients were receiving rapid-onset fentanyl to treat their breakthrough pain (either alone or in combination with other medications), showing that rapid-onset fentanyl preparations are the treatment of choice for BTcP caused by bone metastasis for the specialists in our study.

It is important to stress that the use of ROOs varied significantly according to specialty, with the overall percentage of sublingual fentanyl prescriptions being higher among PC physicians. The administration of immediate-release morphine and NSAIDs for BTcP also differs between specialties: PC physicians had a greater predilection for immediate-release morphine, whereas PU specialists preferred NSAIDs as their second most common option after fentanyl formulations. These results show that the criteria for prescribing pharmaceutical treatments for BTcP caused by bone metastases is not homogeneous in clinical practice in Spain.

Conclusions {#S0005}
===========

Overall, the results of our study on patients suffering from bone BTcP show that important aspects of the management of these patients, such as functionality, HRQoL, or other psychosocial determinants, are often overlooked in routine clinical practice. Additionally, our findings underline the need for treatment protocols and specific referral criteria for BTcP patients with bone metastasis in Spain.

Our results show that rapid-onset fentanyl preparations are the treatment of choice for BTcP caused by bone metastasis in clinical practice in Spain. However, they also reveal the different prescribing practices among RO, PC, and PU specialists treating BTcP caused by bone metastases and underscores the need for multidisciplinary BTcP management strategies.
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[^1]: **Abbreviations:** BTcP, breakthrough cancer pain; SD, Standard Deviation.

[^2]: **Abbreviations:** BTcP, breakthrough cancer pain; ECOG, Eastern Cooperative Oncology Group; VAS, visual analog scale.
